中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2014年
30期
4-7
,共4页
免疫,先天%哮喘%白细胞介素4%白细胞介素18%转化生长因子β1
免疫,先天%哮喘%白細胞介素4%白細胞介素18%轉化生長因子β1
면역,선천%효천%백세포개소4%백세포개소18%전화생장인자β1
Immunity,innate%Asthma%Interleukin-4%Interleukin-18%Transforming growth factor betal
目的 观察特异性免疫对儿童支气管哮喘血清白细胞介素4 (IL-4)、白细胞介素18(IL-18)和转化生长因子β1(TGF-β1)水平的影响.方法 将75例支气管哮喘患儿按随机数字表法分为观察组38例和对照组37例.对照组给予药物治疗,观察组在对照组的基础上给予特异性免疫治疗,治疗12个月后比较两组患儿第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、FVC、呼气峰流速(PEF)等肺功能指标及血清IL-4、IL-18和TGF-β1水平,并比较不同治疗效果患儿血清IL-4、IL-18和TGF-β1水平.结果 治疗12个月后,观察组患儿FEV1、FEV1/FVC、FVC和PEF肺功能指标分别为(2.82±0.35)L、(81.65±5.38)％、(3.46±0.45)L和(5.61±1.44) L/s,对照组分别为(2.17±0.29)L、(72.84±4.82)％、(3.24±0.41)L和(5.08±1.35) L/s,两组比较差异有统计学意义(P＜0.05);观察组患儿血清IL-4、IL-18和TGF-β 1水平分别为(5.94±4.76) ng/L、(192.85±54.06)ng/L和(6.17±0.42)μg/L,对照组分别为(7.26 ±5.33) ng/L、(259.61±67.83) ng/L和(6.83±0.48)μg/L,两组比较差异有统计学意义(P＜0.05);不同治疗效果患儿血清IL-4、IL-18和TGF-β1水平差异有统计学意义(P＜0.05).结论 IL-4、IL-18和TGF-β1均参与支气管哮喘患儿的炎性反应,检测血清IL-4、IL-18和TGF-β1水平能够为儿童支气管哮喘的治疗和预后判断提供依据.
目的 觀察特異性免疫對兒童支氣管哮喘血清白細胞介素4 (IL-4)、白細胞介素18(IL-18)和轉化生長因子β1(TGF-β1)水平的影響.方法 將75例支氣管哮喘患兒按隨機數字錶法分為觀察組38例和對照組37例.對照組給予藥物治療,觀察組在對照組的基礎上給予特異性免疫治療,治療12箇月後比較兩組患兒第1秒用力呼氣容積(FEV1)、FEV1/用力肺活量(FVC)、FVC、呼氣峰流速(PEF)等肺功能指標及血清IL-4、IL-18和TGF-β1水平,併比較不同治療效果患兒血清IL-4、IL-18和TGF-β1水平.結果 治療12箇月後,觀察組患兒FEV1、FEV1/FVC、FVC和PEF肺功能指標分彆為(2.82±0.35)L、(81.65±5.38)％、(3.46±0.45)L和(5.61±1.44) L/s,對照組分彆為(2.17±0.29)L、(72.84±4.82)％、(3.24±0.41)L和(5.08±1.35) L/s,兩組比較差異有統計學意義(P＜0.05);觀察組患兒血清IL-4、IL-18和TGF-β 1水平分彆為(5.94±4.76) ng/L、(192.85±54.06)ng/L和(6.17±0.42)μg/L,對照組分彆為(7.26 ±5.33) ng/L、(259.61±67.83) ng/L和(6.83±0.48)μg/L,兩組比較差異有統計學意義(P＜0.05);不同治療效果患兒血清IL-4、IL-18和TGF-β1水平差異有統計學意義(P＜0.05).結論 IL-4、IL-18和TGF-β1均參與支氣管哮喘患兒的炎性反應,檢測血清IL-4、IL-18和TGF-β1水平能夠為兒童支氣管哮喘的治療和預後判斷提供依據.
목적 관찰특이성면역대인동지기관효천혈청백세포개소4 (IL-4)、백세포개소18(IL-18)화전화생장인자β1(TGF-β1)수평적영향.방법 장75례지기관효천환인안수궤수자표법분위관찰조38례화대조조37례.대조조급여약물치료,관찰조재대조조적기출상급여특이성면역치료,치료12개월후비교량조환인제1초용력호기용적(FEV1)、FEV1/용력폐활량(FVC)、FVC、호기봉류속(PEF)등폐공능지표급혈청IL-4、IL-18화TGF-β1수평,병비교불동치료효과환인혈청IL-4、IL-18화TGF-β1수평.결과 치료12개월후,관찰조환인FEV1、FEV1/FVC、FVC화PEF폐공능지표분별위(2.82±0.35)L、(81.65±5.38)％、(3.46±0.45)L화(5.61±1.44) L/s,대조조분별위(2.17±0.29)L、(72.84±4.82)％、(3.24±0.41)L화(5.08±1.35) L/s,량조비교차이유통계학의의(P＜0.05);관찰조환인혈청IL-4、IL-18화TGF-β 1수평분별위(5.94±4.76) ng/L、(192.85±54.06)ng/L화(6.17±0.42)μg/L,대조조분별위(7.26 ±5.33) ng/L、(259.61±67.83) ng/L화(6.83±0.48)μg/L,량조비교차이유통계학의의(P＜0.05);불동치료효과환인혈청IL-4、IL-18화TGF-β1수평차이유통계학의의(P＜0.05).결론 IL-4、IL-18화TGF-β1균삼여지기관효천환인적염성반응,검측혈청IL-4、IL-18화TGF-β1수평능구위인동지기관효천적치료화예후판단제공의거.
Objective To observe the effect of specific immunotherapy on serum interleukin-4 (IL-4),interleukin-18 (IL-18) and transforming growth factor-beta 1 (TGF-β 1) for the treatment of bronchial asthma in children.Methods Seventy-five patients with bronchial asthma in children were divided into observation group(38 cases) and control group(37 cases) by random digits table method.The control group was received drug treatment,the observation group was given specific immunotherapy on the basis of the control group.After 12 months of treatment,the level of forced expiratory volume in 1 second (FEV1),FEV1/forced vital capacity (FVC),FVC,peak expiratory flow (PEF) such as lung function and serum IL-4,IL-18 and TGF-β1 between two groups was compared and the level of serum IL-4,IL-18 and TGF-β1 was compared among different efficacy.Results After 12 months of treatment,the level of FEV1,FEV/FVC,FVC,PEF was (2.82 ± 0.35) L,(81.65 ± 5.38)％,(3.46 ± 0.45) L,(5.61 ± 1.44) L/s in observation group,(2.17 ±0.29) L,(72.84 ±4.82)％,(3.24 ±0.41) L,(5.08 ± 1.35) L/s in control group,and there was significant difference (P ＜ 0.05).After 12 months of treatment,the level of serum IL-4,IL-18 and TGF-β1 was (5.94 ± 4.76) ng/L,(192.85 ± 54.06) ng/L,(6.17 ± 0.42) μ g/L in observation group,(7.26 ± 5.33) ng/L,(259.61 ± 67.83) ng/L,(6.83 ± 0.48) μ g/L in control group,and there was significant difference(P ＜ 0.05).There was significant difference in the level of serum IL-4,IL-18 and TGF-β1 among different efficacy(P ＜ 0.05).Conclusion IL-4,IL-18 and TGF-β 1 in children with bronchial asthma are involved in the inflammatory response,serum IL-4,IL-18 and TGF-β1 levels can provide the basis for the treatment and prognosis of bronchial asthma in children.
